Raymond James Financial
IRD

Raymond James Financial’s Opus Genetics IRD Stock Holding History

Raymond James Financial’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.7K Sell
15,008
-4,500
-23% -$21K ﹤0.01% 5234
2026
Q1 		$88.8K Sell
19,508
-1,000
-5% -$3.46K ﹤0.01% 5060
2025
Q4 		$41.2K Sell
20,508
-2,000
-9% -$4.06K ﹤0.01% 5028
2025
Q3 		$37.1K Buy
22,508
+11,000
+96% +$13.7K ﹤0.01% 4854
2025
Q2 		$10.8K Hold
11,508
– – ﹤0.01% 5893
2025
Q1 		$11.3K Sell
11,508
-3,472
-23% -$3.88K ﹤0.01% 4769
2024
Q4 		$17.8K Buy
+14,980
New +$17.2K ﹤0.01% 4734

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Raymond James Financial's IRD Position: Q2 2026 in Review

Raymond James Financial reduced its Opus Genetics (IRD) stake by 23% in Q2 2026, selling an estimated $21K and leaving 15,008 shares worth $61.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5234.

Raymond James Financial first reported a position in IRD in Q4 2024 and has held it in 7 quarters since. The position peaked at $88.8K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Raymond James Financial held 15,008 shares of Opus Genetics worth $61.7K as of Q2 2026.
  • Raymond James Financial sold 4,500 Opus Genetics shares in Q2 2026, an estimated $21K.
  • Opus Genetics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5234 holding.
  • Raymond James Financial first reported a position in Opus Genetics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Opus Genetics position peaked at $88.8K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.